FindMyKOL
Clinical trialNCT04467723RecruitingPhase 1/PHASE2Interventional

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

SponsorUniversity of Kansas Medical CenterEnrollment25NSCLC Stage IVNSCLC, Recurrent
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • the University of Kansas Cancer Center (kucc)

    Fairway, Kansas, United States

    Not, yet, recruiting
  • the University of Kansas Cancer Center, Westwood Campus

    Kansas City, Kansas, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 May 2022
Primary completion
1 Jan 2027
Completion
31 Aug 2027
Last update posted
28 Jan 2026
Registered enrollment
25
Registry id
NCT04467723
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.